The 20th Congress of the European Hematology Association took place June 11-14, 2015, in Vienna, Austria.

HSCT outcomes ‘encouraging’ in JAKi responders

Print Friendly, PDF & Email


HSCs_being_prepared_for_transplant_credit_Chad_McNeeley_230.jpg
HSCT preparation
Photo by Chad McNeeley

Outcomes of hematopoietic stem cell transplant (HSCT) are encouraging in myelofibrosis (MF) patients who respond well to JAK inhibitors, according to researchers. The group found that patients with the best response to JAK inhibition had a 2-year survival probability of 91% after HSCT, compared to 32% for patients... [Read Article]

Print Friendly, PDF & Email

PI3Kδ/γ inhibitor generates rapid responses in CLL

Print Friendly, PDF & Email


CLL_BM.jpg
Micrograph showing CLL

New research indicates that duvelisib, a dual inhibitor of PI3Kδ and PI3Kγ, can generate rapid partial responses in treatment-naïve patients with chronic lymphocytic leukemia (CLL). The 18 patients in the expansion cohort of a phase 1 study of duvelisib had a median time to response of 3.7 months, according to iwCLL response... [Read Article]

Print Friendly, PDF & Email

Agent reduces fibrosis, improves platelet counts in MF

Print Friendly, PDF & Email


EHA2015_Messe Wien-rev-240.jpg
Messe Wien, site of EHA 2015

The immunotherapeutic agent PRM-151, when given alone or in combination with ruxolitinib, can reduce bone marrow fibrosis and improve platelet counts in patients with myelofibrosis (MF), results of a phase 2 trial suggest. Using a novel assessment technique known as computer-assisted image analysis (CIA), researchers found that... [Read Article]

Print Friendly, PDF & Email

Combo shows promise for heavily pretreated MM

Print Friendly, PDF & Email


angiogenesis_Credit_Louis_Heiser_&_Robert_Ackland_220.jpg
Angiogenesis
Image by Louis Heiser
and Robert Ackland

Combining a novel agent with dexamethasone can produce successful results where other treatments have failed, according to a presentation at the 20th Congress of the European Hematology Association. Researchers tested low-dose dexamethasone in combination with melflufen, a peptidase-targeted therapy and antiangiogenic compound, in a phase... [Read Article]

Print Friendly, PDF & Email

Activin receptors continue to show efficacy in ß-thalassemia

Print Friendly, PDF & Email


EHA2015_attendee_brt_strt_220.jpg
Attendees at the 20th
Congress of the European
Hematology Association

Two very similar activin receptors, luspatercept and sotatercept, continue to show efficacy in patients with ß-thalassemia, according to research presented at the 20th Congress of the European Hematology Association. The “twin compounds” basically differ from each other in the receptor type, but... [Read Article]

Print Friendly, PDF & Email

Drug won’t advance to phase 3 in ß-thalassemia

Print Friendly, PDF & Email


thalassemia_blood_smear_230.jpg
Blood smear showing
thalassemia

Data from a phase 2a trial suggest the activin receptor sotatercept can effectively treat patients with ß-thalassemia. However, the companies developing the drug have decided not to advance sotatercept to phase 3 trials in this patient population. Instead, the companies are initiating a phase 3 program with sotatercept’s “twin” activin... [Read Article]

Print Friendly, PDF & Email

Jury still out on combo for elderly AML

Print Friendly, PDF & Email


doc_and_patient_older_woman_Credit_NIH_230.jpg
Doctor and patient
Photo courtesy of NIH

A 2-drug combination can produce complete responses (CRs) in elderly patients with newly diagnosed acute myeloid leukemia (AML), but whether the treatment confers a survival benefit remains to be seen. The combination consists of the HDAC inhibitor pracinostat and the antineoplastic agent azacitidine. In a phase... [Read Article]

Print Friendly, PDF & Email

Triplet can provide clinical benefit in rel/ref MM

Print Friendly, PDF & Email


multiple_myeloma_240.jpg
Micrograph showing MM

Combination therapy consisting of the HDAC6 inhibitor ricolinostat, pomalidomide, and dexamethasone can provide a clinical benefit for patients with relapsed and refractory multiple myeloma (MM), according to a researchers. In a phase 1b/2 trial, the triplet produced an overall response rate (ORR) of 29% and a clinical benefit rate of 50%. The... [Read Article]

Print Friendly, PDF & Email

Combo delays progression in relapsed CLL

Print Friendly, PDF & Email


CLL_BM.jpg
Micrograph showing CLL

Results of the COMPLEMENT 2 trial indicate that adding ofatumumab to treatment with fludarabine and cyclophosphamide (OFC) can improve some outcome measures in patients with relapsed chronic lymphocytic leukemia (CLL), when compared to fludarabine and cyclophosphamide alone (FC). Patients who received OFC had a significantly higher overall response rate and longer median... [Read Article]

Print Friendly, PDF & Email

Dose reductions make ponatinib safer for CP-CML

Print Friendly, PDF & Email


Administering ponatinib at lower doses can reduce the risk of arterial occlusive events (AOE) without hindering responses in patients with chronic-phase chronic myeloid leukemia (CP-CML), data from the PACE trial suggest. When earlier results of this phase 2 study showed that ponatinib can cause AOEs, trials of the drug were put on partial clinical hold. Enrollment was stalled temporarily,... [Read Article]
Print Friendly, PDF & Email

JAK inhibitor can provide long-term disease control in PV

Print Friendly, PDF & Email


Polycythemia_vera_blood_smear_Credit_AFIP_230.jpg
Blood smear showing PV
Image courtesy of AFIP

Updated results from the phase 3 RESPONSE trial suggest the JAK1/2 inhibitor ruxolitinib can provide long-term disease control in patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. At 18 months of follow-up, 80% of patients had achieved a durable response to... [Read Article]

Print Friendly, PDF & Email

mAb produces responses in AL amyloidosis

Print Friendly, PDF & Email


amyloidosis_cardiac_micrograph_showing_240.jpg
Cardiac amyloidosis

A monoclonal antibody (mAb) can produce responses in patients with light chain (AL) amyloidosis and persistent organ dysfunction, according to research presented at the 20th Congress of the European Hematology Association. In an ongoing phase 1/2 trial, the mAb, known as NEOD001, produced a cardiac response in 57% of evaluable patients and a... [Read Article]

Print Friendly, PDF & Email

Drug may be ‘important treatment option’ for AML

Print Friendly, PDF & Email


ravandi_farhad_MD_ASH_230.jpg
Farhad Ravandi, MD
Photo courtesy of ASH

Adding the anticancer quinolone derivative vosaroxin to treatment with cytarabine can improve outcomes for some older patients with relapsed/refractory acute myeloid leukemia (AML), results of the phase 3 VALOR trial suggest. AML patients age 60 and older with refractory and early relapse disease had improved survival rates... [Read Article]

Print Friendly, PDF & Email